Pathological mechanism

Data

Name AD combined treatment with cholinesterase inhibitor and alpha-adrenergic agonist.

Description

Hypothesis Nicotinic Receptor Hypothesis Show Other

Extracelular pathological element beta Amyloid Show Other

Intracelular pathological element

Pathological action Inhibits Show Other

Process

Process action

Transmitter(s) Acetylcholine Show Other

Receptor(s)

Channel(s)

Pharmacological Agent Clonidine Show Other THA Show Other

Pharmacological Action

Brain region

Neuron

Cell model

Cellular compartment

PubMed ID 10088136

Citation

AlzWeb

Notes "... (A study) suggests that degeneration of the LC noradrenergic system and the cholinergic cells of the basal forebrain have different functional consequences during the progression of AD. Finally, a combined treatment with noradrenergic and cholinergic drugs might produce a qualitatively broader effect on cognitive functions than either of the treatments alone, and more effectively attenuate clinical dementia" (Riekkenin P and Riekkenin M 1999).

Pathology Alzheimer Show Other

Stage Early Show Other

Question Exclude - no pathology

Claim